AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

aTYR PHARMA INC Director's Dealing 2018

Feb 8, 2018

34337_dirs_2018-02-08_dad4777f-fc9f-4708-9f47-90ee4b075975.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2018-02-06

Reporting Person: King David John (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-06	Employee Stock Option (right to buy)	$3.30	A	150000	Acquired	2028-02-06	Common Stock (150000)	Direct

Footnotes

F1: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2018, such that this option will be fully exercisable on February 6, 2022. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.